WASHINGTON, D.C., April 1, 2013 (GLOBE NEWSWIRE) -- The United States Hispanic Chamber of Commerce (USHCC) commends sBioMed for its groundbreaking product, Steriplex SD. The product is a revolutionary sporicidal disinfectant which can play a major role in combating healthcare-related infection rates in hospitals nationwide.
sBioMed leads the industry in developing breakthrough, patented antimicrobial technologies. The company's flagship product Steriplex SD is the first and only Clostridium difficile sporicide and broad-spectrum, which has proven to be remarkably safe, completely non-fuming, non-corrosive, and contains no bleach.
Nearly 100,000 people die in the US each year from preventable Healthcare-Associated Infections (HAI's). Steriplex SD, which underwent over 500 studies and has been EPA-registered, is now on the market for full commercialization.
"sBioMed is an industry leader in developing infection-control products and the USHCC is proud to highlight innovative entrepreneurial ventures, " said USHCC President & CEO Javier Palomarez. "Steriplex SD has the potential to save countless lives in our nation's hospitals, protecting both patients and caregivers."
The environmentally-friendly product will also reduce healthcare costs. sBioMed is a dynamic start-up, with its main operations in Utah. The company's prospects for rapid growth are promising.
Palomarez added: "This is a wonderful example of American ingenuity that is both noble in purpose and commercially viable."
For more information about STERIPLEX, please visit: http://www.steriplex.com/
About the USHCC
Founded in 1979, the USHCC actively promotes the economic growth and development of Hispanic entrepreneurs and represents the interests of over 3 million Hispanic-owned businesses across the United States that contribute in excess of $465 billion to the American economy each year. It also serves as the umbrella organization for more than 200 local Hispanic chambers and business associations in the United States and Puerto Rico.
About sBioMed®
sBioMed® is a biomedical research firm headquartered in Utah. With decades and multi millions invested in research and development, sBioMed® has achieved monumental scientific breakthroughs with the advent of STERIPLEX infection control technology. sBioMed® technologies are protected by significant EPA registrations and sixty-one U.S. and global patents.